<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130961</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-OTH-IRE-2009/1</org_study_id>
    <nct_id>NCT01130961</nct_id>
  </id_info>
  <brief_title>Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand</brief_title>
  <official_title>Management of Advanced Non-Small Cell Lung Cancer and Clinical Outcomes in Patients Who Received Gefitinib (IRESSA) in Tertiary Care Setting in Thailand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine progression-free survival of lung cancer patients
      who received gefitinib in clinical practice in Thailand.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>median time from the first date of treatment until date of disease progression during Jan 2004- Dec 2008 or 5 years approx.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum response</measure>
    <time_frame>Median time from the first date of treatment until the date that the disease can be maximum controlled during Jan 2004- Dec 2008 or 5 years approx.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>time from the first date of treatment until date of patients dead during Jan 2004- Dec 2008 or 5 years approx.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of EGFR &amp; KRAS mutation from laboratory result</measure>
    <time_frame>During Jan 2004- Dec 2008 or 5 years approx.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">104</enrollment>
  <condition>Lung Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Lung cancer patients admitted in Chulalongkorn and Siriraj hospitals between January 2004
        and December 2008 and treated with gefitinib for at least 3 months
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed as having lung cancer based on histological/cytological findings

          -  Admitted to the hospital between January 2004 and December 2008

          -  Treated with gefitinib for at least 3 months

        Exclusion Criteria:

          -  Involvement in the planning and/or conduct of the study

          -  Participation in another clinical study during the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virote Sriuranpong, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn Hospital, Bangkok, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vichien Srimuninnimit, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Siriraj Hospital, Bangkok, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <last_update_submitted>October 6, 2010</last_update_submitted>
  <last_update_submitted_qc>October 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>MC MD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Advanced NSCLC</keyword>
  <keyword>Gefitinib</keyword>
  <keyword>Thai patient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

